Accenture (ACN)
(Delayed Data from NYSE)
$376.86 USD
+1.71 (0.46%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $377.24 +0.38 (0.10%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$376.86 USD
+1.71 (0.46%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $377.24 +0.38 (0.10%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth B Momentum B VGM
Zacks News
Timing the Market, Is it Possible? - September 28, 2020
by Zacks Equity Research
Is the ability to time the markets more of a data-driven science or a 'gut - feeling' art?
Top Analyst Reports for P&G, Verizon & Thermo Fisher
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Procter & Gamble (PG), Verizon Communications (VZ) and Thermo Fisher Scientific (TMO).
NVEE vs. ACN: Which Stock Is the Better Value Option?
by Zacks Equity Research
NVEE vs. ACN: Which Stock Is the Better Value Option?
Company News for Sep 25, 2020
by Zacks Equity Research
Companies in the news are: DRI, ACN, JBL, FDS
Accenture's (ACN) Q4 Earnings & Revenues Miss Estimates
by Zacks Equity Research
Accenture's (ACN) fourth-quarter fiscal 2020 earnings and revenues decrease on a year-over-year basis.
Accenture Proclaims Project on Pediatric Leukemia Research
by Zacks Equity Research
Built on Accenture (ACN) research, the approach offers a more informed assessment of clinical and genomic data.
Accenture (ACN) Lags Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Accenture (ACN) delivered earnings and revenue surprises of -2.30% and -0.67%, respectively, for the quarter ended August 2020. Do the numbers hold clues to what lies ahead for the stock?
Accenture (ACN) to Benefit From N3 Acquisition: Here's How
by Zacks Equity Research
The acquisition is expected to complement Accenture's (ACN) existing artificial intelligence and machine-learning capabilities.
Is a Beat in the Cards for Accenture (ACN) in Q4 Earnings?
by Zacks Equity Research
Accenture's (ACN) fourth-quarter fiscal 2020 revenues are expected to have declined year over year.
Why the Earnings Surprise Streak Could Continue for Accenture (ACN)
by Zacks Equity Research
Accenture (ACN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Analysts Estimate Accenture (ACN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Accenture (ACN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Accenture (ACN) to Snap Up German Technology Consultancy
by Zacks Equity Research
The buyout complements Accenture's (ACN) capabilities in enterprise resource-planning systems and cloud solutions.
Here's Why You Should Hold Accenture (ACN) in Your Portfolio
by Zacks Equity Research
Acquisitions are one of the key growth strategies for Accenture (ACN).
NVEE or ACN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
NVEE vs. ACN: Which Stock Is the Better Value Option?
Accenture to Use InCountry's Solution in Its Cloud Platform
by Zacks Equity Research
The move is part of Accenture's (ACN) continuous efforts to invest in emerging technologies capable of creating value for the company's clients across the world.
Accenture Announces Sale of Stake in Its Bit2win Business
by Zacks Equity Research
Bit2win's senior management team, along with 25 personnel, is expected to move from Accenture (ACN) to the new company.
The Truth About Market Timing - August 31, 2020
by Zacks Equity Research
Is the ability to time the markets more of a data-driven science or a 'gut - feeling' art?
Oil Service Firms Accelerate Digital Push to Navigate Coronavirus
by Nilanjan Choudhury
The pandemic has acted as a catalyst in shifting from the traditional drilling and fracking system and changing the way of exploring for oil and gas.
NVEE vs. ACN: Which Stock Is the Better Value Option?
by Zacks Equity Research
NVEE vs. ACN: Which Stock Is the Better Value Option?
Bright Near-Term Outlook for Consulting Services Industry
by Shuvra Shankar Dey
Digitization and adoption of technologies have become keys in helping the industry sail through these testing times.
Accenture and Intel to Aid a Robotic Arm-Development Project
by Zacks Equity Research
The project will receive funding and technology from Accenture (ACN), Intel's neuromorphic technology and Applied Brain Research's algorithm.
Accenture Extends Tech Relationship With Anglo American
by Zacks Equity Research
The move should benefit Accenture's (ACN) Resources segment that caters to mining companies among others.
Why Should You Retain Accenture (ACN) in Your Portfolio?
by Zacks Equity Research
Acquisitions enable Accenture (ACN) to enter new markets while diversifying and broadening its product portfolio.
Accenture to Gain From Creative Drive Buyout: Here's How
by Zacks Equity Research
The latest buyout is expected to help Accenture (ACN) enhance its digital capabilities through accelerated content creation.
When Does Market Timing Actually Work? - August 11, 2020
by Zacks Equity Research
Is the ability to time the markets more of a data-driven science or a 'gut - feeling' art?